Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s11934-011-0232-y.pdf
Reference45 articles.
1. • Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist. 2011;16(2):45–50. This article is a review of the treatment of kidney cancer in 2011.
2. Motzer RJ. New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview. Oncologist. 2011;16(2):1–3.
3. •• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8. This article reports the efficacy of a new tyrosine kinase inhibitor in a first-line setting of mRCC.
4. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT Trial. J Clin Oncol. 2011;29(suppl: LBA 308).
5. •• Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011;16(suppl2):32–44. The author addresses the importance of prevention and treatment of adverse events of the targeted therapies to ensure efficacy.
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer;Molecules;2023-01-11
2. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system;Expert Opinion on Drug Safety;2021-12-31
3. SEC61G is upregulated and required for tumor progression in human kidney cancer;Molecular Medicine Reports;2021-04-07
4. Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression;International Journal of Molecular Medicine;2019-03-14
5. Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine;Radiology;2017-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3